Additional file 2: of Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines

Table S1. Plasma analytes assessed in referent normal subjects and in patients undergoing anthracycline therapy. Table S2. Linear regression of biomarkers at V1 to changes in Ejection Fraction > 10% from V1 to V6). (PDF 186 kb)